Literature DB >> 15331912

Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats.

Vijay Pal Singh1, Chandrashekhar S Patil, Naveen K Jain, Shrinivas K Kulkarni.   

Abstract

The objective of the present study was to determine the effect of a selective cyclooxygenase-2 (COX-2) inhibitor in in-vivo dextran sodium sulfate (DSS)-stimulated distal colon tissues of the rat. Longitudinal colon tissue sections from DSS-treated rats exhibited noticeable inflammation, altered contraction, increased myleoperoxidase activity, and oxidative stress. When the animals were pretreated with celecoxib, a selective COX-2 inhibitor, the flare of the colon was further worsened in terms of all the parameters studied. There was a reduction in PGE2 levels on chronic administration of celecoxib in DSS-treated animals. The results of the present study suggest that COX-2 enzyme and prostaglandins derived from COX-2 might play a defensive role in protecting ulceration of the colon akin to that seen in the upper gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331912     DOI: 10.1159/000079135

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  11 in total

Review 1.  Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.

Authors:  Michael Maes
Journal:  Metab Brain Dis       Date:  2012-07-07       Impact factor: 3.584

Review 2.  Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction?

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

3.  Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2.

Authors:  Hua Jiang; Chang-Sheng Deng; Ming Zhang; Jian Xia
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

4.  The role of PGE2 in intestinal inflammation and tumorigenesis.

Authors:  David C Montrose; Masako Nakanishi; Robert C Murphy; Simona Zarini; Jeremy P McAleer; Anthony T Vella; Daniel W Rosenberg
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-10-22       Impact factor: 3.072

5.  Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice.

Authors:  James A Lin; Junji Watanabe; Nora Rozengurt; Ajay Narasimha; Martin G Martin; Jenny Wang; Jonathan Braun; Robert Langenbach; Srinivasa T Reddy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-04-25       Impact factor: 3.072

6.  The GPR55 antagonist CID16020046 protects against intestinal inflammation.

Authors:  A Stančić; K Jandl; C Hasenöhrl; F Reichmann; G Marsche; R Schuligoi; A Heinemann; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 3.598

7.  Punicalagin inhibits inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4-mediated MAPKs and NF-κB activation.

Authors:  Xiaolong Xu; Peng Yin; Changrong Wan; Xinlu Chong; Mingjiang Liu; Peng Cheng; Jiajia Chen; Fenghua Liu; Jianqin Xu
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 8.  A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies.

Authors:  George J DeMarco; Elizabeth A Nunamaker
Journal:  Comp Med       Date:  2019-12-20       Impact factor: 0.982

9.  Increase in gastric acid-induced afferent input to the brainstem in mice with gastritis.

Authors:  P Holzer; T Wultsch; M Edelsbrunner; M Mitrovic; A Shahbazian; E Painsipp; E Bock; M A Pabst
Journal:  Neuroscience       Date:  2007-02-14       Impact factor: 3.590

10.  Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis.

Authors:  Scott S Short; Jin Wang; Shannon L Castle; G Esteban Fernandez; Nancy Smiley; Michael Zobel; Elizabeth M Pontarelli; Stephanie C Papillon; Anatoly V Grishin; Henri R Ford
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.